NASDAQ$CVRX
CVRx Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
CVRx's Q4 2021 financial performance more than doubled, driven by Barostim adoption and salesforce expansion.
CVRx reported a significant increase in revenue for Q4 2021, driven by the successful launch of Barostim for heart failure in the United States. Total revenue was $3.7 million, a 75% increase compared to the same period in the prior year. The company is focused on driving accelerated adoption by executing on its commercial strategy, which includes the continued expansion of its salesforce and the efforts to educate healthcare providers and consumers on the benefits of Barostim.
- Revenue increased by 75% to $3.7 million compared to Q4 2020.
- U.S. revenue increased by 244% to $2.9 million compared to Q4 2020.
- U.S. HF revenue totaled $2.7 million, with 95 HF revenue units.
- Gross profit increased by 63% to $2.7 million compared to Q4 2020.
Headline financials
Revenue & EPS history
CVRx · Revenue · Quarterly
$3.66M
Forward guidance
The Company expects to report total revenue between $3.6 million and $4.0 million for the first quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+36.7%
Q3 2024
Best reaction
-39.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.7% | -13.3% | -29.2% | |
| Q4 2025 | -13.0% | -14.8% | +32.3% | |
| Q3 2025 | +0.8% | -3.4% | -8.5% | |
| Q1 2025 | -39.0% | -32.0% | -15.7% | |
| Q4 2024 | -7.2% | -8.4% | -28.8% | |
| Q3 2024 | +36.7% | +30.2% | +48.8% | |
| Q2 2024 | -17.5% | -14.4% | +3.3% | |
| Q1 2024 | -33.8% | -39.7% | -55.0% | |
| Q4 2023 | -1.4% | -6.1% | -19.6% | |
| Q3 2023 | -1.2% | +0.5% | +50.4% | |
| Q2 2023 | +6.2% | +5.7% | +2.3% | |
| Q1 2023 | +24.0% | +34.2% | +41.1% | |
| Q4 2022 | +3.1% | +5.9% | -24.2% | |
| Q3 2022 | +2.7% | +21.4% | +43.1% | |
| Q2 2022 | +22.1% | +24.6% | +4.6% | |
| Q1 2021 | -3.4% | -12.0% | -6.3% | |
| Q1 2022 | +12.6% | +28.5% | +14.0% | |
| Q4 2021 | +0.9% | +0.0% | -21.2% | |
| Q3 2021 | +4.8% | +4.1% | -36.5% | |
| Q2 2020 | -4.7% | -13.0% | -13.0% | |
| Q2 2021 | -5.6% | -7.5% | -15.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro